Epilepsy – Praxis PRAX-628-322
Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.
A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)
Inclusion Criteria:
- Has a diagnosis of focal onset epilepsy according to the International League Against Epilepsy Classification of Epilepsy (2017).
- Prior to randomization, past evidence by CT or MRI that has ruled out a progressive cause of epilepsy in the judgement of the investigator and/or in consultation with the medical monitor.
- Participant must attest to be taking stable doses of 1 or up to 3 acceptable ASMs for at least 4 weeks prior to screening and during screening prior to Day 1.
- Has at least 4 countable focal onset seizures during the 4 weeks of Observation Period immediately prior to randomization with no more than 21 days seizure free during this period.
- Seizure diary must be completed for ≥80% days in the Observation Period.
- Other criteria may apply
Complete the form to get connected with new research studies and our team will reach out soon to help determine your eligibility.
